Anaphylaxis, Dose-Ranging Hurdles May Trip Teva's Reslizumab
This article was originally published in Scrip
Executive Summary
Even though GlaxoSmithKline PLC's recently approved Nucala (mepolizumab) – the first anti-interleukin-5 (IL-5) treatment in the US for adults and adolescents with severe asthma with an eosinophilic phenotype – has paved the way for Teva Pharmaceutical Industries Ltd.'s reslizumab, when the latter drug goes before an advisory committee later this week, it must clear its own hurdles, which includes anaphylaxis and muscle toxicity, along with limited dose-ranging data, which may trip up the experimental medicine in the end.